Drug intelligence / Profile preview

Immunyr

Development stage: Preclinical
Lead developer: Kanyr Pharma
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Parenteral

Overview

**Immunyr** is Kanyr Pharma's proprietary ex vivo dendritic cell-based therapeutic cancer-vaccine platform. Patient-derived dendritic cells are pharmacologically activated with proprietary small-molecule protein tyrosine phosphatase inhibitors to enhance cytokine secretion and antigen-presentation capacity, then combined with tumor-specific antigens to stimulate anti-tumor immune responses. The platform is intended to support personalized therapeutic vaccines across multiple cancers. ([kanyrpharma.com](https://kanyrpharma.com/technology))

Other names: ImmunyrTM

Beyond the preview

Go deeper on Immunyr.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunyr.

Explore the full profile